Dafna D Gladman1. 1. Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, University Health Network, University of Toronto, 399 Bathurst Street, Toronto, Ontario, 1E-410B, Canada. dafna.gladman@utoronto.ca.
Abstract
PURPOSE OF REVIEW: To review current understanding of the prevalence, clinical features, outcome measures and recent therapeutic trials in axial psoriatic arthritis (axPsA). RECENT FINDINGS: The prevalence of axPsA is estimated at 40-50%. However, the definition of axPsA remains unclear, therefore these estimates may be inaccurate. Ax PsA appears to be distinct from ankylosing spondylitis in demographic, clinical, genetic and therapeutic features. Because of the lack of widely accepted definition of axPsA it has been difficult to design therapeutic trials for this domain of PsA. Several studies have demonstrated the uniquness of axPsA. Few recent trials suggest that therapies that work for peripheral arthritis also work for axPsA.
PURPOSE OF REVIEW: To review current understanding of the prevalence, clinical features, outcome measures and recent therapeutic trials in axial psoriatic arthritis (axPsA). RECENT FINDINGS: The prevalence of axPsA is estimated at 40-50%. However, the definition of axPsA remains unclear, therefore these estimates may be inaccurate. AxPsA appears to be distinct from ankylosing spondylitis in demographic, clinical, genetic and therapeutic features. Because of the lack of widely accepted definition of axPsA it has been difficult to design therapeutic trials for this domain of PsA. Several studies have demonstrated the uniquness of axPsA. Few recent trials suggest that therapies that work for peripheral arthritis also work for axPsA.
Authors: Dafna D Gladman; Robert D Inman; Richard J Cook; Desirée van der Heijde; Robert B M Landewé; Jurgen Braun; John C Davis; Philip Mease; Joachim Brandt; Ruben Burgos Vargas; Vinod Chandran; Philip Helliwell; Arthur Kavanaugh; Finbar D O'Shea; Muhammad A Khan; Nicolo Pipitone; Proton Rahman; John D Reveille; Millicent A Stone; William Taylor; Douglas J Veale; Walter P Maksymowych Journal: J Rheumatol Date: 2007-07-01 Impact factor: 4.666
Authors: Vinod Chandran; Finbar D O'Shea; Catherine T Schentag; Robert D Inman; Dafna D Gladman Journal: J Rheumatol Date: 2007-11-15 Impact factor: 4.666
Authors: Laure Gossec; Xenofon Baraliakos; Andreas Kerschbaumer; Maarten de Wit; Iain McInnes; Maxime Dougados; Jette Primdahl; Dennis G McGonagle; Daniel Aletaha; Andra Balanescu; Peter V Balint; Heidi Bertheussen; Wolf-Henning Boehncke; Gerd R Burmester; Juan D Canete; Nemanja S Damjanov; Tue Wenzel Kragstrup; Tore K Kvien; Robert B M Landewé; Rik Jozef Urbain Lories; Helena Marzo-Ortega; Denis Poddubnyy; Santiago Andres Rodrigues Manica; Georg Schett; Douglas J Veale; Filip E Van den Bosch; Désirée van der Heijde; Josef S Smolen Journal: Ann Rheum Dis Date: 2020-06 Impact factor: 27.973